TY - DATA T1 - GSK669 exhibits NOD2 selectivity in cells that express endogenous NOD1 and NOD2. PY - 2013/08/01 AU - David J. Rickard AU - Clark A. Sehon AU - Viera Kasparcova AU - Lorena A. Kallal AU - Xin Zeng AU - Monica N. Montoute AU - Tushar Chordia AU - Derek D. Poore AU - Hu Li AU - Zining Wu AU - Patrick M. Eidam AU - Pamela A. Haile AU - Jong Yu AU - John G. Emery AU - Robert W. Marquis AU - Peter J. Gough AU - John Bertin UR - https://plos.figshare.com/articles/figure/_GSK669_exhibits_NOD2_selectivity_in_cells_that_express_endogenous_NOD1_and_NOD2_/761933 DO - 10.1371/journal.pone.0069619.g003 L4 - https://ndownloader.figshare.com/files/1139774 KW - biotechnology KW - drug discovery KW - immunology KW - Immune system KW - cytokines KW - immunity KW - Immune activation KW - immunotherapy KW - inflammation KW - Innate immunity KW - autoimmunity KW - immunomodulation KW - Molecular cell biology KW - Signal transduction KW - Signaling pathways KW - chemical biology KW - medicinal chemistry KW - exhibits KW - nod2 KW - selectivity KW - cells KW - endogenous KW - nod1 N2 - Concentration response curves of GSK669 and its close analogue GSK400 for the inhibition of MDP (A) but not Tri-DAP (B) stimulated IL-8 secretion in HCT116 cells which express functionally active NOD1 and NOD2. Cells were pre-incubated with compounds for 1 hour prior to addition of NOD agonists. IL-8 secreted into medium was assayed after 24 hours. The same RIP2 inhibitor used in Figure 2C was included as a positive control. Data are the average percent inhibition obtained from 1 (RIP2), 2 (GSK400) or 4 (GSK669) separate experiments. ER -